4
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: not found

      IGFBP2 activates the NF-κB pathway to drive epithelial-mesenchymal transition and invasive character in pancreatic ductal adenocarcinoma

      research-article
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The molecular basis underlying the particularly aggressive nature of pancreatic ductal adenocarcinoma (PDAC) still remains unclear. Here we report evidence that the insulin-like growth factor-binding protein IGFBP2 acts as a potent oncogene to drive its extremely malignant character. We found that elevated IGFBP2 expression in primary tumors was associated with lymph node metastasis and shorter survival in PDAC patients. Enforced expression of IGFBP2 promoted invasion and metastasis of PDAC cells in vitro and in vivo by inducing NF-κB-dependent epithelial-mesenchymal transition (EMT). Mechanistic investigations revealed that IGFBP2 induced the nuclear translocation and phosphorylation of the p65 NF-κB subunit through the PI3K/Akt/IKKβ pathway. Conversely, enforced expression of PTEN blunted this signaling pathway and restored an epithelial phenotype to PDAC cells in the presence of overexpressed IGFBP2. Overall, our results identify IGFBP2 as a pivotal regulator of an EMT axis in PDAC, the activation of which is sufficient to confer the characteristically aggressive clinical features of this disease.

          Related collections

          Author and article information

          Journal
          2984705R
          2786
          Cancer Res
          Cancer Res.
          Cancer research
          0008-5472
          1538-7445
          5 November 2016
          22 September 2016
          15 November 2016
          15 November 2017
          : 76
          : 22
          : 6543-6554
          Affiliations
          [1 ]Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
          [2 ]Department of Pancreatic Carcinoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China
          [3 ]Department of Pathology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin, PR China
          [4 ]Department of Pathology, Tianjin Huanhu Hospital, Tianjin, PR China
          [5 ]Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
          [6 ]Department of Molecular and Cellular Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
          [7 ]Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, NC, USA
          Author notes
          Corresponding authors: Wei Zhang, PhD, Department of Cancer Biology, Comprehensive Cancer Center of Wake Forest Baptist Medical Center, Winston-Salem, NC 27157, USA; Phone: 336-713-7508 wezhang@ 123456wakehealth.edu ; or Jihui Hao, MD, PhD, Department of Pancreatic Carcinoma, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Cancer, Key Laboratory of Cancer Prevention and Therapy, Tianjin PR China, 300060, Phone: 8622-2334-0123; haojihui@ 123456tjmuch.com
          Article
          PMC5315491 PMC5315491 5315491 nihpa827007
          10.1158/0008-5472.CAN-16-0438
          5315491
          27659045
          a10d3fab-7e49-4f93-9a9c-342913007a0f
          History
          Categories
          Article

          insulin-like growth factor–binding protein 2,epithelial-mesenchymal transition,pancreatic ductal adenocarcinoma,metastasis,p65

          Comments

          Comment on this article